Mingyi Chen

10.4k total citations · 3 hit papers
198 papers, 6.5k citations indexed

About

Mingyi Chen is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Mingyi Chen has authored 198 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Molecular Biology, 53 papers in Oncology and 42 papers in Immunology. Recurrent topics in Mingyi Chen's work include Optical measurement and interference techniques (31 papers), Advanced Measurement and Metrology Techniques (24 papers) and Immune Cell Function and Interaction (17 papers). Mingyi Chen is often cited by papers focused on Optical measurement and interference techniques (31 papers), Advanced Measurement and Metrology Techniques (24 papers) and Immune Cell Function and Interaction (17 papers). Mingyi Chen collaborates with scholars based in United States, China and Japan. Mingyi Chen's co-authors include Tatsuya Sawamura, Τοmoh Masaki, Hongwei Guo, Peter Tontonoz, Haitao He, William J. Murphy, Shuh Narumiya, Arta M. Monjazeb, Sean B. Joseph and Bryan Laffitte and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Mingyi Chen

184 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

2002 778 citations Mingyi Chen et al. profile →
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

2020 370 citations Mingyi Chen et al. profile →
Severely polarized extracellular acidity around tumour cells

2024 80 citations Qiang Feng, Tongyi Huang et al. Nature Biomedical Engineering profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mingyi Chen United States	41	2.3k	2.1k	1.7k	1.4k	682	198	6.5k
Christine Decaestecker Belgium	52	2.2k 1.0×	3.5k 1.6×	1.6k 1.0×	534 0.4×	937 1.4×	287	8.7k
Bin Li China	48	1.6k 0.7×	2.4k 1.1×	2.0k 1.2×	1.8k 1.3×	1.0k 1.5×	421	7.9k
Keisuke Izumi Japan	34	739 0.3×	1.3k 0.6×	654 0.4×	457 0.3×	584 0.9×	228	4.4k
Yuqi Yang China	44	705 0.3×	2.5k 1.2×	1.2k 0.7×	284 0.2×	896 1.3×	240	6.2k
Franco Mosca Italy	50	620 0.3×	2.1k 1.0×	2.4k 1.4×	5.8k 4.3×	506 0.7×	401	10.5k
James T. Handa United States	54	875 0.4×	3.9k 1.8×	378 0.2×	498 0.4×	446 0.7×	203	9.3k
Isabelle Salmon Belgium	57	2.3k 1.0×	3.9k 1.8×	2.7k 1.6×	1.2k 0.9×	1.6k 2.3×	352	11.2k
Isao Nakanishi Japan	49	1.0k 0.4×	2.8k 1.3×	2.1k 1.2×	1.3k 0.9×	2.2k 3.3×	372	9.8k
Jin Hwan Kim South Korea	39	315 0.1×	2.0k 0.9×	534 0.3×	702 0.5×	339 0.5×	238	6.2k
Itaru Endo Japan	62	1.1k 0.5×	2.6k 1.2×	7.4k 4.4×	6.6k 4.9×	2.1k 3.2×	830	16.4k

Countries citing papers authored by Mingyi Chen

Since Specialization

Citations

This map shows the geographic impact of Mingyi Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingyi Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingyi Chen more than expected).

Fields of papers citing papers by Mingyi Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingyi Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingyi Chen. The network helps show where Mingyi Chen may publish in the future.

Co-authorship network of co-authors of Mingyi Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Mingyi Chen. A scholar is included among the top collaborators of Mingyi Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingyi Chen. Mingyi Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Xinbin, Wenqiang Sun, Yanhong Zhang, et al.. (2025). TAp63γ is the primary isoform of TP63 for tumor suppression but not development. Cell Death Discovery. 11(1). 51–51.

Wu, Yumeng, et al.. (2024). Circular Chromosome Conformation Capture (4C-Seq) Analysis of HBV-Host Chromosome DNA Interactome. Methods in molecular biology. 2837. 45–58.

Feng, Qiang, Tongyi Huang, Brandon Faubert, et al.. (2024). Severely polarized extracellular acidity around tumour cells. Nature Biomedical Engineering. 8(6). 787–799. 80 indexed citations breakdown →

Wirsik, Naita M., Mingyi Chen, Alexander Quaas, et al.. (2024). Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma. Cancer Medicine. 13(7). e6866–e6866. 3 indexed citations

Fuda, Franklin, Flavia Rosado, Samuel John, et al.. (2024). Clinicopathologic features of relapsed CD19(−) B‐ALL in CD19‐targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B‐cell marker for CD19(−) B lymphoblasts. International Journal of Laboratory Hematology. 46(3). 503–509. 1 indexed citations

Zheng, Ruifang, et al.. (2023). Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19. Cancers. 15(14). 3598–3598. 3 indexed citations

Botten, Giovanni A., Yuannyu Zhang, Yoon Jung Kim, et al.. (2023). Structural Variation Cooperates with Permissive Chromatin to Control Enhancer Hijacking-Mediated Oncogenic Transcription. Blood. 142(4). 336–351. 11 indexed citations

Yan, Wensheng, Wenqiang Sun, Yanhong Zhang, et al.. (2023). Isoform-specific disruption of the TP73 gene reveals a critical role for TAp73γ in tumorigenesis via leptin. eLife. 12. 5 indexed citations

Ji, Yuan, Jun Wang, Qi Shen, et al.. (2022). Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature. Modern Pathology. 35(7). 865–874. 7 indexed citations

10.

Zhang, Yanhong, et al.. (2022). Ferredoxin reductase and p53 are necessary for lipid homeostasis and tumor suppression through the ABCA1–SREBP pathway. Oncogene. 41(12). 1718–1726. 17 indexed citations

11.

Mohibi, Shakur, Jin Zhang, Mingyi Chen, & Xinbin Chen. (2021). Mice Deficient in the RNA-Binding Protein Zfp871 Are Prone to Early Death and Steatohepatitis in Part through the p53–Mdm2 Axis. Molecular Cancer Research. 19(10). 1751–1762. 5 indexed citations

12.

Sun, Wenqiang, et al.. (2021). Fine-tuning p53 activity by modulating the interaction between eukaryotic translation initiation factor eIF4E and RNA-binding protein RBM38. Genes & Development. 35(7-8). 542–555. 7 indexed citations

13.

Li, Kailong, Yuannyu Zhang, Xin Liu, et al.. (2020). Noncoding Variants Connect Enhancer Dysregulation with Nuclear Receptor Signaling in Hematopoietic Malignancies. Cancer Discovery. 10(5). 724–745. 30 indexed citations

14.

Lu, Tianshi, Shidan Wang, Lin Xu, et al.. (2020). Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Science Immunology. 5(44). 30 indexed citations

15.

Liu, Zhida, Chuanhui Han, Chunbo Dong, et al.. (2019). Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science Immunology. 4(38). 35 indexed citations

16.

Zhang, Jin, Enshun Xu, Cong Ren, et al.. (2018). Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN. Cancer Research. 78(6). 1511–1521. 26 indexed citations

17.

Lucchesi, Christopher A., Jin Zhang, Buyong Ma, Mingyi Chen, & Xinbin Chen. (2018). Disruption of the Rbm38-eIF4E Complex with a Synthetic Peptide Pep8 Increases p53 Expression. Cancer Research. 79(4). 807–818. 34 indexed citations

18.

Su, Ruijun, Ralph Green, & Mingyi Chen. (2017). Enumeration of bone marrow plasmacytoid dendritic cells by multiparameter flow cytometry as a prognostic marker following allogeneic hematopoietic stem cell transplantation. Blood Cells Molecules and Diseases. 69. 107–112. 2 indexed citations

19.

Monjazeb, Arta M., Michael S. Kent, Steven K. Grossenbacher, et al.. (2016). Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Clinical Cancer Research. 22(17). 4328–4340. 91 indexed citations

20.

Pai, Chien-Chun Steven, Hui-Hua Hsiao, Kai Sun, et al.. (2014). Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels. Biology of Blood and Marrow Transplantation. 20(12). 1899–1904. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact